The clinical use of denosumab for the management of low bone mineral density in postmenopausal women

Journal of Pharmacy Practice

Volumn 25, Issue 3, 2012, Pages 310-318

  Harris, Kira B ^a,b   Nealy, Kimberly L ^a,c   Jackson, Delilah J ^a,d   Thornton, Phillip L ^a  

^a WINGATE UNIVERSITY   (United States)

^b Crown Point Family Physicians   (United States)

^c CAROLINAS MEDICAL CENTER   (United States)

^d Kannapolis Internal Medicine   (United States)

Author keywords

bone mineral density; denosumab; fracture; osteoporosis; receptor activator of nuclear factor B ligand (RANKL)

Indexed keywords

ALENDRONIC ACID; CALCIUM; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PHOSPHORUS; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

APPENDICITIS; ARTICLE; BONE DENSITY; CELLULITIS; DIVERTICULITIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG USE; ECZEMA; FLATULENCE; HIP FRACTURE; HUMAN; IMMUNE DEFICIENCY; INFECTION; NEOPLASM; NONHUMAN; PATIENT COMPLIANCE; PNEUMONIA; POSTMENOPAUSE OSTEOPOROSIS; PYELONEPHRITIS; RISK FACTOR; SEPSIS; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84864266910     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190012442061     Document Type: Article

References (48)

1. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporosis Int. 2005 ; 16 (suppl 2). S3 - S7
2. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis Int. 2006 ; 17 (12). 1726-1733 (Pubitemid 44607392)
3. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med. 1989 ; 149 (11). 2445-2448 (Pubitemid 19283200)
4. Cooper C. Osteoporosis: disease severity and consequent fracture management. Osteoporosis Int. 2010 ; 21 (suppl 2). S425 - S429
5. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation ; 2010 :
6. Medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010 ; 16 (suppl 3). 1-37
7. Sipos W, Pietschmann P, Rauner M, et al. Pathophysiology of osteoporosis. Wien Med Wochenschr. 2009 ; 159 (9-10). 230-234
8. Who are candidates for prevention and treatment of osteoporosis. Osteoporosis Int. 1997 ; 7: 1-6
9. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007 ; 22 (3). 465-475 (Pubitemid 46797130)
10. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI) ; 2011 :
11. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA. 1999 ; 282 (7). 637-645 (Pubitemid 29384151)
12. Chesnut CH, Silverman S, Engelhardt M, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000 ; 109 (4). 267-276
13. Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res. 2005 ; 20 (9). 1514-1524 (Pubitemid 41243540)
14. Siris ES, Harris ST, Roxen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006 ; 81 (8). 1013-1022 (Pubitemid 44175011)
15. Hiligsmann M, Rebenda V, Gathon HJ, et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int. 2010 ; 86 (3). 202-210
16. Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007 ; 82 (12). 1493-1501 (Pubitemid 350211697)
17. Bekker PJ, Holloway DL, Rasussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004 ; 19 (7). 1059-1066 (Pubitemid 41110556)
18. Bock O, Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis-optimizing efficacy in clinical practice. Clin Interv Aging. 2008 ; 3 (2). 279-297 (Pubitemid 352037868)
19. Prolia (denosumab) [product information]. Breda: Amgen Europe B.V.; 2010. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001120/WC500093526.pdf. Accessed September 17, 2011.
20. McClung MR, Lewiecki M, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006 ; 354 (8). 821-831 (Pubitemid 43290920)
21. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008 ; 93 (6). 2149-2157 (Pubitemid 351831529)
22. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009 ; 361 (8). 756-765
23. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009 ; 24 (1). 153-161
24. Miller PD, Wagman RB, Peacock M, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab. 2011 ; 96 (2). 394-402
25. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008 ; 43 (2). 222-229
26. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011 ; 96 (4). 972-980
27. Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011 ; 26 (3). 530-537
28. Johnston CC, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women. Arch Intern Med. 2000 ; 160 (22). 3444-3450
29. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007 ; 22 (12). 1832-1841 (Pubitemid 351229299)
30. Seeman E, Pierre DD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010 ; 25 (8). 1886-1894
31. Genant HK, Engelke K, Hanley DA, et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone. 2010 ; 47 (1). 131-139
32. Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010 ; 25 (10). 2256-2265
33. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996 ; 348 (9041). 1535-1541 (Pubitemid 26411651)
34. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998 ; 280 (24). 2077-2082 (Pubitemid 29014065)
35. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999 ; 282 (14). 1344-1352 (Pubitemid 29483192)
36. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000 ; 11 (1). 83-91 (Pubitemid 30099515)
37. Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004 ; 19 (8). 1241-1249 (Pubitemid 41094364)
38. Jamal SA, Ljunggren O, Stehman-Breen C, et al. The effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011 ; 26 (8). 1829-1835
39. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010 ; 25 (1). 72-81
40. Black DM, Schwartz AV, Ensrud KR, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA. 2006 ; 296 (24). 2927-2938 (Pubitemid 46021497)
41. Ferrari-Lacraz S, Ferrari S. Do RANKL inhibitors (Denosumab) affect inflammation and immunity?. Osteoporos Int. 2011 ; 22 (2). 435-446
42. Rizzoli R, Reginster JY, Boonen S, et al. Adverse reaction and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011 ; 89 (2). 91-104
43. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008 ; 74 (11). 1385-1393
44. Food & Drug Administration. Background document for meeting of advisory committee for reproductive health drugs: Denosumab. August2009. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/ drugs/reproductivehealthdrugsadvisorycommittee/ucm176623.pdf. Accessed July 1, 2011.
45. 2010 position statement of the North American menopause society. Menopause. 2010 ; 17 (1). 23-56
46. Kendler DL, Bessette L, Hill CD, et al. Preference and satisfaction with a 6-mont subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int. 2010 ; 21 (5). 837-846
47. Kendler DL, McClung MR, Freemantle N, et al. Adherence, preference, and satisfaction of postmenopausal women taking Denosumab or alendronate. Osteoporos Int. 2011 ; 22 (6). 1725-1735
48. Cramer JA, Gold DT, Silverman SL, et al. Systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007 ; 18 (8). 1023-1031 (Pubitemid 47019996)